On April 30, Chengdu Kanghong Pharmaceutical Group Co.Ltd(002773) (hereinafter referred to as ” Chengdu Kanghong Pharmaceutical Group Co.Ltd(002773) “) disclosed the transcript of 2021. Last year, the company achieved an operating revenue of 3.605 billion yuan, a year-on-year increase of 9.4%, and the net profit attributable to shareholders of listed companies was 421 million yuan, turning losses into profits year-on-year. According to the first quarter report of 2022 disclosed on the same day, the company achieved revenue and net profit attributable to the parent company in the first quarter of this year were 895 million yuan and 297 million yuan respectively, showing a steady development trend on the whole.
As a listed pharmaceutical enterprise, Chengdu Kanghong Pharmaceutical Group Co.Ltd(002773) adheres to the strategy of “innovation driven development” and perseveres to make the company stand out from the current situation of non prominent clinical characteristics, serious product homogenization, low-level duplication and so on. According to the annual report of 2021, among the 18 drugs listed by the company, 12 varieties are exclusive, 13 varieties enter the national medical insurance catalogue and 7 varieties enter the national essential drug catalogue, becoming a representative new drug innovation enterprise in China.
From the perspective of the industry, the sales revenue and profits of the pharmaceutical industry are considered to maintain a sustained growth trend. Enterprises with patented drugs will not only win the rapid development of the market, but also achieve the rapid growth of profits. According to the data, Chengdu Kanghong Pharmaceutical Group Co.Ltd(002773) Chinese patent medicine, chemical medicine and biological products contributed 1.084 billion yuan, 1.191 billion yuan and 1.32 billion yuan to the company’s operating revenue in 2021 respectively, of which the revenue growth of Chinese patent medicine and biological products reached 18.91% and 21.45% year-on-year respectively.
In 2021, Chengdu Kanghong Pharmaceutical Group Co.Ltd(002773) guided by clinical needs, continued to increase investment, in-depth research and professional innovation in Ophthalmology, brain, tumor and other fields, and continuously launched high-quality new products urgently needed in clinic, so as to further consolidate the company’s dominant position in the core treatment field.
In terms of R & D, in order to consolidate the continuous innovation ability of new drug R & D, Chengdu Kanghong Pharmaceutical Group Co.Ltd(002773) is based on key technical fields (industrialization technology of macromolecular protein drugs, standardized quality control technology of the whole industrial chain of Chinese patent medicines, new preparation technology of solid oral drugs, green synthesis technology of chemical raw materials). Focus on the core treatment fields (Ophthalmology, brain, tumor). The company has set up four major sectors: New Drug Research Institute, Biological New Drug Research Institute, product technology center and medical research center, and integrated advantageous resources and professional cooperation at home and abroad. It has achieved certain leading advantages in product innovation and technology improvement.
In the gene therapy sector, the R & D team is developing an adeno-associated virus (AAV) delivery system with independent intellectual property rights, which is characterized by tissue specificity, immunogenicity, expression controllability and infection efficiency. Based on this technology, the products developed by the company are aimed at major diseases of chronic diseases. For example, kh631, a product that delivers target genes through AAV, has shown sustained efficacy in preclinical disease models. It is expected to submit a clinical trial application in 2022. In terms of synthetic biotechnology, kh617, which is used to treat advanced solid tumors and recurrent glioblastoma, has shown good results in preclinical research. The safety evaluation experiment has been completed in the first quarter of 2022, and the application for clinical trial is expected to be submitted in 2022. Several global patent applications have been completed for the above projects.
Looking forward to 2022, Chengdu Kanghong Pharmaceutical Group Co.Ltd(002773) said that it would further improve the R & D innovation system, strengthen the production mode of excellence, continue the business philosophy of “market driven sales”, and continue to implement active human resources policies to promote the high-quality and sustainable development of enterprises.
Ke Xiao, President of the company, said that Chengdu Kanghong Pharmaceutical Group Co.Ltd(002773) will continue to take innovation as the driving force, development as the foundation, market as the center and quality as the life, strengthen management, reduce costs, improve quality, increase benefits and control risks, and make every effort to promote major research projects to ensure fast and efficient; We should adapt to the new industrial policy and regulatory environment, innovate marketing strategies and models, further improve and optimize organizational structure and corporate governance ability, strengthen execution, and strive to achieve double growth of operating revenue and net profit.
